Skip to main
MLYS
MLYS logo

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics Inc. is positioned positively due to its proprietary product candidate, lorundrostat, which has shown the ability to deliver a substantial placebo-adjusted blood pressure (BP) benefit exceeding 10 mmHg in patients with uncontrolled and resistant hypertension. The company benefits from a differentiated therapeutic profile that stands out against competitors, particularly highlighted by recent discussions with key opinion leaders (KOLs) regarding favorable Phase 3 data. Additionally, there is optimism surrounding an imminent FDA feedback and anticipated New Drug Application (NDA) submission, which could further bolster the company's growth prospects.

Bears say

Mineralys Therapeutics faces significant challenges that negatively impact its stock outlook, primarily due to uncertainties surrounding the market potential of its product candidate, lorundrostat, which may not achieve projected peak commercial revenues due to factors like market size and pricing strategies. Furthermore, the company could struggle to secure the necessary capital resources to sustain its operations, jeopardizing future developmental and commercialization efforts. The potential for increased observed hyperkalemia levels, as highlighted by key opinion leaders, raises additional concerns regarding the drug's safety profile, which may further hinder its market acceptance and financial viability.

MLYS has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 5 analysts, MLYS has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.